Back to LCT Homepage Targeting Huntington's Disease, Stroke, Type 1 Diabetes and Haemophilia
Living Cell Technologies
LCT - Living Cell Technologies

News

News updates: Subscribe
Unsubscribe

Archive

June 5, 2008
LCT Expands Diabetes Clinical Trial
>more
June 3, 2008
LCT Lists on International OTCQX
>more
May 21, 2008
LCT interviewed by New Zealand TV program, Close Up
>video
May 12, 2008
LCT presents encapsulation technology at conference
>more
May 8, 2008
LCT features on Channel Ten News
>more
>video
May 8, 2008
LCT prepares to list on international OTCQX
>more
 

News

LCT lodges application for clinical trial of its type 1
diabetes treatment
August 24, 2006

Living Cell Technologies Ltd (ASX:LCT) today announced it has lodged an application with the New Zealand regulator MedSafe to conduct a Phase I/IIa clinical trial of its type 1 diabetes cell therapy product DiabeCell.

DiabeCell is a porcine pancreatic cell product for the treatment of insulin-dependent diabetes. The neo-natal pig cells produce insulin and help regulate blood glucose levels appropriate to the amount of glucose detected in the blood stream of the diabetic recipient.

Related Document
Download ( = 44Kb )

LCT - Living Cell Technologies

Q & A

What is xenotransplantation?
The use of living animal cells, tissues or organs in human therapeutics. >more

What is DiabeCell?
DiabeCell is a porcine pancreatic cell product for the treatment of insulin-dependent diabetes. >more

What is NeurotrophinCell?
A choroid plexus (brain) cell product with the potential to treat diseases of the nervous system such as Huntington's disease and stroke. >more

What is LCT's encapsulation technology?
The living cells are covered in a seaweed-derived coating (alginate encapsulation) to form capsules which eliminate the
need for toxic immunosuppressant drugs and allow the release of beneficial factors. >more
 
HomeContactSitemapLegalsPrivacy
  
graphic design and website design - PDF Communications Ltd